Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
News

Adverse events reported for HPV vaccine

Laura Eggertson
CMAJ November 06, 2007 177 (10) 1169-1170; DOI: https://doi.org/10.1503/cmaj.071454
Laura Eggertson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2007 Canadian Medical Association

As 4 provinces began immunizing schoolgirls to prevent the human papillomavirus, a watchdog group in the United States warned of dangerous adverse events stemming from the vaccine's delivery — concern government regulators dismiss.

Figure

Quebec recently became the fifth province to announce its HPV plans, unveiling a “voluntary” program that will vaccinate girls as early as grade 4. Image by: Lisa F. Young / iStockphoto

Public health officials in Ontario, Nova Scotia, Prince Edward Island and Newfoundland and Labrador began administering the Merck Frosst vaccine Gardasil to select groups of girls (grades 6, 7 or 8) in September, just as the US advocacy group Judicial Watch released documents obtained through Freedom of Information indicating that 3 deaths and 1637 adverse events occurred after the vaccine was administered (prior to May 15).

Judicial Watch acknowledged, however, that it did not analyze the adverse events data from a medical perspective. “We wanted to get the information out in a public light. … It's out there for people who know more than us to interpret,” program manager Dee Grothe said, adding that the organization's main concern is that the vaccine not be mandated by state governments.

The adverse events data comes from the US Food and Drug Administration's Vaccine Adverse Event Reporting System. According to the Centers for Disease Control and Prevention in Atlanta, as of June 30, there were 2531 adverse reports, including 9 deaths, out of 7 million doses dispensed. The figures, however, can include multiple reports of the same event, since physicians, manufacturers and patients report to the same system.

Health Canada, meanwhile, received 82 adverse event reports out of 162 000 doses distributed as of Aug. 17. Five adverse events required hospitalization, including 2 later determined to be appendicitis. One patient fainted, 1 event appears related to a viral infection, and 1 appears related to encephalopathy, which Health Canada is investigating.

“This is not unusual,” says Dr. Theresa Tam, director of the Public Health Agency of Canada's Immunization and Respiratory Infections Division. “Every new vaccine that comes on the market, people monitor the safety profile, and inevitably, there are things that occur following immunization.”

Neither the product monograph nor permission forms that parents (in Ottawa, for example) receive from local public health authorities contain a list of possible adverse events, such as deaths, following administration of Gardasil.

Although Canadian authorities are aware of the US reports, the deaths are not listed as possible adverse events because there is no scientific evidence proving a causal relationship with the vaccine, says Tam. “At this point, there is nothing that I can see that is of particular concern. … It's what we probably would expect to see based on the clinical trials and the background rates of some of these conditions.”

Centers for Disease Control and Prevention spokesman Curtis Allen says all deaths and other serious adverse events requiring hospitalization are investigated. The agency has classified 5% of vaccine-reported events as “serious.” The most common reactions have been pain at the injection site, general pain, nausea, dizziness and fainting. The incidence of fainting is slightly higher than the background rate normally expected among that age group, Allen says. As a result, “we're suggesting that physicians keep patients in their office for 15 minutes after administering the vaccine.”

Some of the 9 deaths were duplicate reports, while 1 patient turned out to be “very much alive,” Allen added. There are 4 confirmed deaths in girls or women who received the HPV vaccine, but it is not known to have caused any of those deaths.

In 2 cases, women died after suffering pulmonary embolisms, but they were also taking birth control pills, a known risk factor, says Allen. In 2 other instances, girls had influenza, and myocarditis resulted in the death of 1 of those patients.

“The deaths do not appear to be connected at all with the vaccine,” Allen says. “It appears to be a very safe and effective vaccine and we believe it's very important to women's health.”

Sheila Murphy, a spokesperson for Merck Frosst in Canada, says the company's worldwide database on adverse events, which is shared with regulators, does not indicate there's a need for a change in the product monograph or “some kind of an announcement. … There are always adverse events with anything, whether they're related to the product or not is always the question.”

Murphy says there's been intense media attention surrounding the vaccine “because it's about sex. And also cancer.”

As HPV vaccines are administered to girls who are not yet sexually active and haven't been exposed to the virus, critics fear it confers tacit approval of premarital intercourse. Others worry that vaccination will reduce Pap test screening or will prove ineffective over time. Still others question the vaccine's value for money.

Concerns have also been expressed about Merck's political influence, having hired lobbyists well-connected to Prime Minister Stephen Harper and Ontario Health Minister George Smitherman. The federal government provided $300 million in the last federal budget for provincial vaccination campaigns.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 177 (10)
CMAJ
Vol. 177, Issue 10
6 Nov 2007
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adverse events reported for HPV vaccine
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Adverse events reported for HPV vaccine
Laura Eggertson
CMAJ Nov 2007, 177 (10) 1169-1170; DOI: 10.1503/cmaj.071454

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Adverse events reported for HPV vaccine
Laura Eggertson
CMAJ Nov 2007, 177 (10) 1169-1170; DOI: 10.1503/cmaj.071454
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Patient education
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire